Results 1 to 10 of about 269,227 (256)

TYROSINE KINASE INHIBITORS AND INTERFERON

Mediterranean Journal of Hematology and Infectious Diseases, 2014
The use of interferon-a (INF) in chronic myeloid leukemia, when it started in the 80s, was considered as a breakthrough in the therapy of this disease; INF administered alone or in combination with aracytine was the standard choice for treatment for
Maria Dimou, Panagiotis Panagiotidis
doaj   +4 more sources

TYROSINE KINASE INHIBITORS AND PREGNANCY

Mediterranean Journal of Hematology and Infectious Diseases, 2014
The management of patients with chronic myeloid leukemia (CML) during pregnancy has became recently a matter of continuous debate.  The introduction of the Tyrosine Kinase Inhibitors (TKIs) in clinical practice has dramatically changed the prognosis of ...
Elisabetta Abruzzese, Malgorzata Monika Trawinska, Paolo De Fabritiis, Alessio Pio Perrotti   +3 more
doaj   +4 more sources

Treatment of anaplastic lymphoma kinase-positive lung adenocarcinoma with pemetrexed and carboplatin after crizotinib failure and significant liver dysfunction; a case report

Cancer Treatment and Research Communications, 2021
Tyrosine kinase inhibitors are the first-line treatment for Anaplastic Lymphoma Kinase-positive lung adenocarcinomas. However, chemotherapy is still an option in patients who are unresponsive or intolerant of tyrosine kinase inhibitors.
Oranus Mohammadi, Kayla Haines, Mohammad Jahanzeb   +2 more
doaj   +1 more source

Second‐line therapy with first‐ or second‐generation tyrosine kinase inhibitors in EGFR‐mutated non‐small cell lung cancer patients with T790M‐negative or unidentified mutation

Thoracic Cancer, 2021
Background T790M mutation causes resistance to tyrosine kinase inhibitors (TKIs) in approximately 49% of patients with epidermal growth receptor‐mutant non‐small cell lung cancer (NSCLC).
Tadashi Nishimura, Tomohito Okano, Masahiro Naito, Soichi Iwanaka, Ayaka Ohiwa, Yasumasa Sakakura, Taro Yasuma, Hajime Fujimoto, Corina N. D'Alessandro‐Gabazza, Yasuhiro Oomoto, Tetsu Kobayashi, Esteban C. Gabazza, Hidenori Ibata   +12 more
doaj   +1 more source

Analysis of Tumor Heterogeneity Through AXL Activation in Primary Resistance to EGFR Tyrosine Kinase Inhibitors

JTO Clinical and Research Reports, 2023
Introduction: EGFR tyrosine kinase inhibitors are standard therapeutic agents for patients with advanced NSCLC harboring EGFR mutations. Nevertheless, some patients exhibit primary resistance to EGFR tyrosine kinase inhibitors in the first-line treatment
Ryota Nakamura, MD, Hiroyuki Fujii, MD, Tadaaki Yamada, MD, PhD, Yohei Matsui, MD, Takeshi Yaoi, MS, Mizuki Honda, MD, Noriyuki Tanaka, MD, PhD, Aya Miyagawa-Hayashino, MD, PhD, Akihiro Yoshimura, MD, PhD, Kenji Morimoto, MD, PhD, Masahiro Iwasaku, MD, PhD, Shinsaku Tokuda, MD, PhD, Young Hak Kim, MD, PhD, Eiichi Konishi, MD, PhD, Kyoko Itoh, MD, PhD, Koichi Takayama, MD, PhD   +15 more
doaj   +1 more source

QTC Changes Associated with Tyrosine Kinase Inhibitors in Cancer Patients

Pakistan Armed Forces Medical Journal, 2022
Objective: To look for QTc changes associated with Tyrosine Kinase inhibitors and factors related to these changes among patients suffering from cancer. Study Design: Comparative cross-sectional study.
Rahimullah Khattak, Riaz Ahmad, Muhammad Nadeem, Huma Amjad, Amjad Khan, Ibtisam .   +5 more
doaj   +1 more source

Efficacy of Next-Generation EGFR-TKIs in Patients With Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials

Technology in Cancer Research & Treatment, 2020
Background: The efficacy of next-generation epidermal growth factor receptor-tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer who have failed first-generation epidermal growth factor receptor-tyrosine kinase inhibitors ...
Yi-Tian Qi MM, Yi Hou PhD, Liang-Chen Qi MD   +2 more
doaj   +1 more source

Identification of tyrosine kinase inhibitors that halt Plasmodium falciparum parasitemia.

PLoS ONE, 2020
Although current malaria therapies inhibit pathways encoded in the parasite's genome, we have looked for anti-malaria drugs that can target an erythrocyte component because development of drug resistance might be suppressed if the parasite cannot mutate ...
Kristina Kesely, Panae Noomuna, Michal Vieth, Philip Hipskind, Kasturi Haldar, Antonella Pantaleo, Francesco Turrini, Philip S Low   +7 more
doaj   +1 more source

Tyrosine Kinase Inhibitors as Antiangiogenic Drugs in Multiple Myeloma

Pharmaceuticals, 2010
Tyrosine kinase inhibitors are a new class of anticancer drugs, that are capable of directly interacting with the catalytic site of the target enzyme and thereby inhibiting catalysis. Therapeutically useful tyrosine kinase inhibitors are not specific for
Domenico Ribatti
doaj   +1 more source

Factors associated with efficacy of first-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer

Tumor Biology, 2017
The finding of epidermal growth factor receptor tyrosine kinase inhibitors, which reflects a classical process of translational research, is a critical milestone for non-small-cell lung cancer treatment.
Shaohua Cui, Liyan Jiang
doaj   +1 more source